Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 7/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697882 | 1.00 | ITK (0.50) | ITKKIF11MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL13115653 | 0.85 | ABL1 (0.48) | ITKMAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL30310978 | 0.85 | ITK (0.45) | ITKKIF11MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL14493350 | 0.84 | MAP2K4 (0.53) | ITKMAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL29937023 | 0.83 | ITK (0.40) | ITKMAP2K4MAPK1MAPKAPK3MAPK6 | |
| SCHEMBL31552439 | 0.79 | ITK (0.53) | ITKKIF11MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL2826429 | 0.79 | NOS1 (0.39) | ITKMAP2K4 | |
| SCHEMBL12247 | 0.79 | ITK (0.53) | ITKKIF11MAP2K4MAPK1MAPKAPK3 | |
| SCHEMBL497271 | 0.78 | PDPK1 (0.60) | ITK | |
| SCHEMBL1330584 | 0.76 | PDPK1 (0.63) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024006379-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | AXONIS THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| WO-2014100463-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140171432-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382893-A1 | AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY | ZC3HAV1, ZC3HAV1L, IFNAR1 | ITK 2554/4885KIF11 4103/4885MAP2K4 3860/4885 |
| US-20260015351-A1 | METHODS AND COMPOUNDS FOR INHIBITING MKK7 ENZYMES | PRKCSH, MAPK7, PRKCB | ITK 4047/4885KIF11 1488/4885MAP2K4 227/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | ITK 4359/4885KIF11 3110/4885MAP2K4 3056/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | ITK 4532/4885KIF11 4561/4885MAP2K4 2855/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | ITK 207/4885KIF11 4243/4885MAP2K4 772/4885 |
| US-20140171432-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM5C | ITK 4220/4885KIF11 4326/4885MAP2K4 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.